Results 71 to 80 of about 3,492,883 (216)

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors

Frontiers in Pharmacology, 2022
Erlotinib is a highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor for the targeted therapy of non-small-cell lung cancer (NSCLC) However, the efficacy of erlotinib is limited because the development of drug ...
Xi-xi Hou, Xiao-qing Gong, Long-fei Mao, Ge Sun, Ge Sun, Jian-xue Yang, Jian-xue Yang   +6 more
doaj   +1 more source

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab [PDF]

Cancer Biology & Therapy, 2011
The epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase (RTK) and is recognized as a key mediator of tumorigenesis in many human tumors. Currently there are five EGFR inhibitors used in oncology, two monoclonal antibodies (panitumumab, and cetuximab) and three tyrosine kinase inhibitors (erlotinib, gefitinib ...
Toni M, Brand, Emily F, Dunn, Mari, Iida, Rebecca A, Myers, Kellie T, Kostopoulos, Chunrong, Li, Chimera R, Peet, Deric L, Wheeler   +7 more
openaire   +2 more sources

p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair

Neoplasia: An International Journal for Oncology Research, 2021
EGFR signaling promotes ovarian cancer tumorigenesis, and high EGFR expression correlates with poor prognosis. However, EGFR inhibitors alone have demonstrated limited clinical benefit for ovarian cancer patients, owing partly to tumor resistance and the
Victor CY Mak, Xinran Li, Ling Rao, Yuan Zhou, Sai-Wah Tsao, Lydia WT Cheung   +5 more
doaj   +1 more source

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming. [PDF]

, 2016
The impact of EGFR-mutant NSCLC precision therapy is limited by acquired resistance despite initial excellent response. Classic studies of EGFR-mutant clinical resistance to precision therapy were based on tumor rebiopsies late during clinical tumor ...
Bagai, Rakesh, Bivona, Trever G, Danielpour, David, Feng, Yan, Leahy, Patrick, Lindner, Daniel, Ma, Patrick C, Rosell, Rafael, Shi, Ivy, Thiagarajan, Praveena S, Veigl, Martina, Wu, Xiaoliang, Yin, Lihong, Zhang, Wei, Zhang, Zhenfeng   +14 more
core   +1 more source

GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells

Frontiers in Cell and Developmental Biology
Epidermal growth factor receptor (EGFR) is a major oncogenic protein, and thus EGFR-targeting therapies are widely used in patients with various types of cancer, including lung cancer. However, resistance to EGFR inhibitors, such as erlotinib, presents a
Fumiya Ito, Wakiko Iwata, Yoshihiro Adachi, Hiromi Sesaki, Miho Iijima   +4 more
doaj   +1 more source

BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis

Advanced Science, 2023
Erlotinib, an EGFR tyrosine kinase inhibitor, is used for treating patients with cancer exhibiting EGFR overexpression or mutation. However, the response rate of erlotinib is low among patients with gastric cancer (GC).
Fangyuan Li, Junxian Yu, Tao Pan, Haoran Feng, Jianfang Li, Beiqin Yu, Zhiyuan Fan, Qingqing Sang, Mengdi Chen, Mingde Zang, Junyi Hou, Xiongyan Wu, Yingyan Yu, Yuan‐Yuan Li, Chao Yan, Zhenggang Zhu, Liping Su, Bingya Liu   +17 more
doaj   +1 more source

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. [PDF]

, 2017
Casitas B-lineage lymphoma (CBL) is an E3 ubiquitin ligase and a molecule of adaptor that we have shown is important for non-small-cell lung cancer (NSCLC). We investigated if MET is a target of CBL and if enhanced in CBL-altered NSCLC.
Batra, Surinder K, Husain, Aliya N, Mirzapoiazova, Tamara, Salgia, Ravi, Sharma, Sherven, Srivastava, Minu K, Tan, Yi-Hung Carol, Vokes, Everett E, Won, Brian M, Zhu, Li   +9 more
core   +1 more source

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. [PDF]

, 2017
PurposeCabozantinib is a multi-kinase inhibitor that targets MET, AXL, and VEGFR2, and may synergize with EGFR inhibition in NSCLC. Cabozantinib was assessed alone or in combination with erlotinib in patients with progressive NSCLC and EGFR mutations who
Engelman, Jeffrey, Gettinger, Scott, Jänne, Pasi A, Lara, Primo N, Leach, Joseph, Miles, Dale R, Subramaniam, Deepa S, Wakelee, Heather A, Wax, Michael, West, Howard, Yaron, Yifah   +10 more
core   +2 more sources

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity [PDF]

, 2016
BACKGROUND: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when cancer is diagnosed at ...
CHERUBINI, EMANUELA, DE VITIS, CLAUDIA, Fabiana Fosca Ferrara, Francesca Bergantino, Francesca Fenizia, Gennaro Ciliberto, GIARNIERI, Enrico, GIOVAGNOLI, Maria Rosaria, Luigi Aurisicchio, MANCINI, RITA, MARIOTTA, Salvatore, Matilde Lambiase, Nicola Normanno, NOTO, ALESSIA, RICCI, Alberto, ROSCILLI, GIUSEPPE, Susan Costantini, TORRISI, Maria Rosaria   +17 more
core   +3 more sources

Substrate‐dependent bidirectional modulation of P‐glycoprotein‐mediated drug resistance by erlotinib [PDF]

Cancer Science, 2009
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) inhibit the function of certain adenosine triphosphate (ATP)‐binding cassette transporters, including P‐glycoprotein/ABCB1 and breast cancer resistance protein (BCRP)/ABCG2. We previously reported an antagonistic activity of gefitinib towards BCRP.
Kohji, Noguchi, Haruka, Kawahara, Airi, Kaji, Kazuhiro, Katayama, Junko, Mitsuhashi, Yoshikazu, Sugimoto   +5 more
openaire   +2 more sources